Pharmaceutical Organizations Announce Key Principles to Foster Supply Chain Security and Integrity

Washington, D.C. (January 30, 2013) The100th meeting of the National Conference of Pharmaceutical Organizations (NCPO) resolved that the member organizations will work together to help further secure the pharmaceutical supply chain.

PhRMA Special 301 Submission 2013

Hurricane Sandy Special Report

PhRMA Applauds Passage of Russia PNTR

Washington, D.C. (December 6, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

“We applaud Congress for approving Permanent Normal Trade Relations (PNTR) for Russia.  Improving trade relationships with Russia will protect and bolster U.S. biopharmaceutical jobs and exports.

Biopharmaceuticals in Medicare, Medicaid and Department of Veterans Affairs

PhRMA Statement on Rx Response’s Pharmacy Status Reporting Tool Activation in 11 States and the District of Columbia

Washington, D.C. (October 31, 2012)-- Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on Rx Response activation in the wake of Hurricane Sandy:

PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement

Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani and Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V):

PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization

Washington, D.C. (June 26, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today regarding reauthorization of the Prescription Drug User Fee Act (PDUFA):

“Today’s Senate passage of S. 3187, the Food and Drug Administration (FDA) Safety and Innovation Act of 2012, is the culmination of a multi-year effort on the part of biopharmaceutical companies, FDA, Congress, and stakeholders that featured unprecedented collaboration, public input, and bipartisanship.

New Study Details Foreign Efforts To Lure Biopharmaceutical Companies

Washington, D.C. (May 17, 2012) — Despite increasing budget pressures, countries around the world are making substantial investments in pro-innovation policies and programs to lure the biopharmaceutical research sector away from the U.S., finds a new study released by Battelle Technology Partnership Practice.

New Research Demonstrates Biopharmaceutical Sector’s Impact on U.S. Economy and Jobs

Washington, D.C. (July 11, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani today issued the following statement on the biopharmaceutical research sector’s impact on jobs and the American economy:
 

Pages

Subscribe to RSS - Access